Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle
Open Access

Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity

Robert Wood, Steve Fermer, Sulabha Ramachandran, Scott Baumgartner and Robert Morlock
The Journal of Rheumatology October 2016, 43 (10) 1897-1903; DOI: https://doi.org/10.3899/jrheum.151199
Robert Wood
From Adelphi Real World, Cheshire, UK; AstraZeneca, Wilmington, Delaware; Ardea Biosciences Inc., San Diego, California, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Robert.Wood@adelphigroup.com
Steve Fermer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sulabha Ramachandran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Baumgartner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Morlock
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Percentage of patients reporting problems performing EQ-5D domain activities or PROMIS HAQ score — patients with inadequately vs adequately controlled gout. A. *Defined for mobility as the sum of percentage of patients with some problems in walking about + percentage confined to bed; for self-care, as sum of percentage with some problems + percentage unable to wash or dress; for usual activities (act), as sum of percentage with some problems + percentage unable to perform usual activities; for pain/discomfort (disc), sum of percentage with moderate + percentage with extreme pain or discomfort; for anxiety/depression (anx/depr), sum of percentage moderately + percentage extremely anxious or depressed. † p < 0.001 vs patients with inadequately controlled gout across the 3 groups of each domain (no, some, or extreme problem). B. Data are mean (95% CI). * p < 0.001 vs patients with inadequately controlled gout.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Percentage of (A) work time missed because of gout, (B) impairment while working due to gout, (C) overall work impairment due to gout, and (D) activity impairment due to gout — patients with inadequately controlled vs adequately controlled gout. Data are mean (95% CI). * p < 0.001 vs patients with inadequately controlled gout.

Tables

  • Figures
    • View popup
    Table 1.

    Baseline patient characteristics.

    CharacteristicAll Patients, N = 1204Patients with Inadequately Controlled Gout, n = 836Patients with Adequately Controlled Gout, n = 368p
    Age, yrs, mean (SD)61.9 (12.3)61.3 (12.7)63.4 (11.4)0.0048
    Male, n (%)986 (81.9)685 (81.9)301 (81.8)1
    Time since diagnosis, months, mean (SD)58.7 (60.3)52.1 (57.4)73.9 (64.0)< 0.0001
    Time receiving current therapy, months, mean (SD)39.9 (49.5)32.2 (44.4)57.4 (55.8)< 0.0001
    Current therapy, n (%)
      Allopurinol922 (76.6)617 (73.8)305 (82.9)0.0005
      Febuxostat261 (21.7)201 (24.0)60 (16.3)0.0024
      Probenecid27 (2.2)26 (3.1)1 (0.3)0.0011
      Other*10 (0.8)8 (1.0)2 (0.5)0.732
    Comorbid conditions, n (%)
      ≥ 1 cardiovascular759 (63.0)527 (63.0)232 (63.0)1
      ≥ 1 gastrointestinal193 (16.0)140 (16.8)53 (14.4)0.348
      ≥ 1 auto-immune46 (3.8)29 (3.5)17 (4.6)0.332
      ≥ 1 renal226 (18.8)161 (19.3)65 (17.7)0.575
      ≥ 1 other479 (39.8)322 (38.5)157 (42.7)0.180
    Tophi, yes, n (%)191 (15.9)138 (16.5)53 (14.4)0.392
    Compliance, yes, n (%)
      Physician-reported1048 (87.0)698 (83.5)350 (95.1)< 0.0001
      Patient-reported1084 (94.0)751 (93.2)333 (96.0)0.078
    Employed, yes, n (%)506 (43.3)362 (44.5)144 (40.6)0.223
    • ↵* “Other” includes benzbromarone, sulfinpyrazone, and pegloticase. For patients with inadequately controlled gout: serum uric acid (sUA) > 6 mg/dl (> 357 µmol/l) or ≥ 2 flares. For patients with adequately controlled gout: sUA ≤ 6 mg/dl (≤ 357 µmol/l) and 0 flares.

    • View popup
    Table 2.

    EQ-5D domain summary scores by prevalence — patients with inadequately vs adequately controlled gout.

    Percent Reporting No/Some/Severe*
    DomainPatients with Inadequately Controlled Gout, N = 836Patients with Adequately Controlled Gout, N = 368p†
    Pain/discomfort41.0/52.3/6.762.2/36.1/1.7< 0.0001
    Mobility55.4/44.2/0.470.8/29.2/0.0< 0.0001
    Usual activities61.3/36.3/2.481.9/17.2/0.8< 0.0001
    Anxiety/depression70.0/27.5/2.482.2/16.2/1.7< 0.0001
    Self-care79.8/19.7/0.590.5/9.5/0.0< 0.0001
    • ↵* No problems, some problems, severe problems.

    • ↵† p values represent the difference between patients with inadequately controlled gout and adequately controlled gout across the 3 groups of each domain.

    • View popup
    Table 3.

    Percentage of patients reporting difficulty performing PROMIS HAQ domain activities — patients with inadequately vs adequately controlled gout.

    Activities% Reporting No/Little/Some/Much Difficulty/Unable to do
    Patients with Inadequately Controlled Gout, N = 836Patients with Adequately Controlled Gout, N = 368p *
    Dress yourself including shoelaces and buttons62.3/25.3/6.2/5.7/0.575.7/17.7/3.6/2.5/0.6< 0.0001
    Shampoo your hair75.1/17.5/5.0/1.8/0.688.1/10.0/1.9/0.0/0.0< 0.0001
    Stand up from armless straight chair61.0/22.1/7.9/8.4/0.674.9/18.0/4.1/2.8/0.3< 0.0001
    Get in/out of bed64.5/24.4/9.0/1.7/0.479.0/14.1/5.5/1.4/0.0< 0.0001
    Cut your own food using eating utensils81.1/12.7/5.1/0.9/0.292.5/6.1/1.1/0.3/0.0< 0.0001
    Lift a full cup/glass to mouth84.7/11.3/2.7/1.2/0.195.8/2.5/1.4/0.3/0.0< 0.0001
    Open a new milk carton76.8/14.7/6.5/1.2/0.985.9/10.5/2.2/1.1/0.30.0002
    Walk outdoors on flat ground58.8/16.2/7.3/17.0/0.780.6/10.3/1.9/7.2/0.0< 0.0001
    Climb up 5 steps53.3/19.3/9.1/17.2/1.170.8/18.9/2.8/7.5/0.0< 0.0001
    Wash/dry your body77.3/16.2/4.8/1.3/0.490.3/6.4/2.5/0.8/0.0< 0.0001
    Take a tub bath68.5/20.7/6.6/2.8/1.480.1/14.0/3.9/1.4/0.6< 0.0001
    Get on/off toilet70.9/16.4/4.9/7.7/0.183.8/11.7/1.7/2.8/0.0< 0.0001
    Reach up and take down a 5-lb object61.0/22.5/8.4/6.8/1.273.9/18.3/4.2/3.4/0.3< 0.0001
    Bend down to pick up clothing from floor55.4/29.5/10.4/4.0/0.767.5/23.6/7.8/1.1/0.0< 0.0001
    Open car doors77.0/17.0/4.8/0.6/0.691.1/7.0/1.4/0.6/0.0< 0.0001
    Open previously opened jars69.9/21.0/6.7/1.6/0.980.3/15.5/3.1/0.3/0.80.0001
    Turn faucet on/off78.9/15.1/5.0/0.9/0.189.5/8.9/1.1/0.6/0.0< 0.0001
    Run errands and shop58.3/18.9/5.1/16.1/1.677.3/11.9/3.6/6.4/0.8< 0.0001
    Get in/out of car58.7/26.7/11.2/3.2/0.374.5/21.9/3.3/0.3/0.0< 0.0001
    Do chores such as vacuuming or yard work48.7/28.4/15.6/4.1/3.364.0/22.9/9.5/2.8/0.8< 0.0001
    Need cane/crutches/walker/wheelchair or help to get around, % yes16.26.4< 0.0001
    Need special chair/raised toilet seat or help to stand up from sitting, % yes7.22.50.001
    Need a buttonhook/zipper pull/gadget or help to get dressed, % yes4.62.80.152
    Need a long-handled appliance or help to reach something, % yes5.73.10.057
    • ↵* P value represents the difference between patients with controlled and uncontrolled gout across the 5 groups of difficulty or in the percent responding “yes.” PROMIS: Patient Reported Outcomes Measurement Information System; HAQ: Health Assessment Questionnaire.

    • View popup
    Table 4.

    Work productivity and daily activities in the past 7 days — patients with inadequately controlled vs adequately controlled gout. Data are mean (90% CI).

    Patients with Inadequately Controlled GoutPatients with Adequately Controlled Goutp
    Hours missed during past 7 days because of gout problems1.6 (1.0–2.3)0.4 (−0.2–1.0)0.001
    Hours missed during past 7 days for other reasons (vacation, etc.)2.8 (1.9–3.7)3.4 (1.8–5.1)0.46
    Hours actually worked during past 7 days35.0 (33.4–36.5)31.5 (28.6–34.4)0.17
    How gout affected productivity at work during past 7 days1.91 (1.64–2.18)0.52 (0.27–0.77)< 0.001
    How gout affected daily activities (not work) during past 7 days2.03 (1.78–2.28)0.53 (0.30–0.75)< 0.001
    • View popup
    APPENDIX 1.

    Calculation of WPAI questionnaire outcomes.

    OutcomeEquation*
    Percentage of work time missed because of healthQ2/(Q2 + Q4) for those who were currently employed
    Percentage of impairment while working because of healthQ5/10 for those who were currently employed and actually worked in the previous 7 days
    Percentage of overall work impairment due to healthQ2/(Q2 + Q4) + ((1 − Q2/(Q2 + Q4)) × (Q5/10)) for those who were currently employed
    Percentage of activity impairment due to healthQ6/10 for all respondents
    • ↵* Results expressed in percentages by multiplying each score by 100. WPAI: Work Productivity and Activity Impairment; Q: question; Q1: currently employed; Q2: hours missed due to health problems; Q3: hours missed for other reasons; Q4: hours actually worked; Q5: degree that health affected productivity while working (using a 0–10 Likert scale); Q6: degree that health affected productivity in regular unpaid activities (0–10 Likert scale).

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 43, Issue 10
1 Oct 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity
Robert Wood, Steve Fermer, Sulabha Ramachandran, Scott Baumgartner, Robert Morlock
The Journal of Rheumatology Oct 2016, 43 (10) 1897-1903; DOI: 10.3899/jrheum.151199

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Patients with Gout Treated with Conventional Urate-lowering Therapy: Association with Disease Control, Health-related Quality of Life, and Work Productivity
Robert Wood, Steve Fermer, Sulabha Ramachandran, Scott Baumgartner, Robert Morlock
The Journal of Rheumatology Oct 2016, 43 (10) 1897-1903; DOI: 10.3899/jrheum.151199
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • APPENDIX 1.
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Keywords

GOUT
HEALTH-RELATED QUALITY OF LIFE
URATE-LOWERING THERAPY
WORK PRODUCTIVITY

Related Articles

Cited By...

More in this TOC Section

  • Clinically Inactive Disease and Remission in Patients With Juvenile Idiopathic Arthritis Receiving Tofacitinib: Post Hoc Analysis of a Phase III Trial
  • Modifiable Lifestyle Factors, Genetic Susceptibility, and Incident Radiographic Axial Spondyloarthritis
  • Comparative Analysis of Damage Accrual in Lupus Nephritis Stratified by Biological Sex
Show more Article

Similar Articles

Keywords

  • GOUT
  • health-related quality of life
  • URATE-LOWERING THERAPY
  • WORK PRODUCTIVITY

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire